- Home
- MDGL vs FCFS Comparison
MDGL vs FCFS Comparison
Compare MDGL & FCFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDGL
- FCFS
- Stock Information
- Founded
- MDGL 2011
- FCFS 1988
- Country
- MDGL United States
- FCFS United States
- Employees
- MDGL N/A
- FCFS N/A
- Industry
- MDGL Biotechnology: Pharmaceutical Preparations
- FCFS Other Specialty Stores
- Sector
- MDGL Health Care
- FCFS Consumer Discretionary
- Exchange
- MDGL Nasdaq
- FCFS Nasdaq
- Market Cap
- MDGL 6.8B
- FCFS 5.9B
- IPO Year
- MDGL N/A
- FCFS 1991
- Fundamental
- Price
- MDGL $275.26
- FCFS $127.91
- Analyst Decision
- MDGL Strong Buy
- FCFS Buy
- Analyst Count
- MDGL 10
- FCFS 3
- Target Price
- MDGL $420.63
- FCFS $133.50
- AVG Volume (30 Days)
- MDGL 335.5K
- FCFS 290.5K
- Earning Date
- MDGL 05-01-2025
- FCFS 07-24-2025
- Dividend Yield
- MDGL N/A
- FCFS 1.19%
- EPS Growth
- MDGL N/A
- FCFS 21.73
- EPS
- MDGL N/A
- FCFS 6.25
- Revenue
- MDGL $317,383,000.00
- FCFS $3,388,567,000.00
- Revenue This Year
- MDGL $285.43
- FCFS $2.67
- Revenue Next Year
- MDGL $63.77
- FCFS $5.58
- P/E Ratio
- MDGL N/A
- FCFS $20.47
- Revenue Growth
- MDGL N/A
- FCFS 5.06
- 52 Week Low
- MDGL $200.63
- FCFS $100.24
- 52 Week High
- MDGL $377.46
- FCFS $135.57
- Technical
- Relative Strength Index (RSI)
- MDGL 38.56
- FCFS 50.75
- Support Level
- MDGL $265.39
- FCFS $126.22
- Resistance Level
- MDGL $275.54
- FCFS $128.99
- Average True Range (ATR)
- MDGL 11.39
- FCFS 2.49
- MACD
- MDGL -1.08
- FCFS -0.58
- Stochastic Oscillator
- MDGL 24.12
- FCFS 35.91
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.
About FCFS FirstCash Holdings Inc.
FirstCash Holdings Inc operates pawn stores in the United States and Latin America. Its primary business involves making small loans secured by personal property. The the company has three reportable segments: U.S. pawn; Latin America pawn; and Retail POS payment solutions (AFF). It derives majority revenue from U.S. Pawn segment. These pawn loans give the borrower the option of either repaying the loans with interest or forfeiting the property without further penalty. Geographically operates in USA, Mexico, Latin America, with maximum revenue from USA.